Psychedelics

401 posts

" Revive Therapeutics (CSE:RVV) & PharmaTher (CSE:PHRM) sign MDMA research collaboration agreement

Revive Therapeutics (RVV), and PharmaTher (PHRM) have signed a research collaboration agreement.
  • Jon Brown
  • 2 mins
  • 03 February 2023 12:15 (EST)
  • 124

" Field Trip Health & Wellness (TSXV:FTHW) begins trading on the OTC Market

Field Trip Health & Wellness (FTHW) has received approval to start trading on the OTCQB Market in the United States.

" Numinus (TSX:NUMI) receives Health Canada approval for psychedelic tea therapy

Numinus Wellness (NUMI) has received approval from Health Canada for its experiential training study.
Small Pharma team

" Small Pharma (TSXV:DMT) adds two new patents to its portfolio approved for issue

Small Pharma (DMT) has had two patents approved by the U.S. Patent & Trademark Office to further build up its portfolio.
  • Jon Brown
  • 2 mins
  • 01 February 2023 13:00 (EST)
  • 90

" Psyched Wellness (CSE:PSYC) adds new bottle size for Amanita Muscaria Extract Calm

Psyched Wellness (PSYC) will launch a new larger bottle size for their Amanita Muscaria Extract (AME-1) product Calm on February 28th.
Cybin - CEO, Doug Drysdale (first from left).

" Cybin (NEO:CYBN) announces first-in-human dosing of its DMT molecule

Cybin (CYBN) will initiate the first-in-human dosing of its proprietary deuterated DMT molecule, CYB004.

" Irwin Naturals (CSE:IWIN) signs LOI to acquire Braxia Scientific (CSE:BRAX)

Irwin Naturals Inc. (IWIN) has signed an amended LOI to acquire medical and psychedelic research company Braxia Scientific Corp. (BRAX).
Irwin Naturals - CEO, Klee Irwin.

" Irwin Naturals (CSE:IWIN) to distribute cannabis products in Oklahoma

Irwin Naturals (IWIN) has signed a licensing agreement with Gold Rush Premium Extracts to produce and distribute THC products in Oklahoma.

" Lobe Sciences (CSE:LOBE) signs agreement with Integrative Headache Medicine of New York

Lobe Sciences Limited (LOBE) has signed an Investigator Initiated Research Agreement with Lauren R. Natbony, MD, FAHS.
Red Light Holland - CEO, Todd Shapiro.

" Red Light Holland (CSE:TRIP) updates on Peterborough mushroom farm

Ontario-based mushroom producer Red Light Holland Corp. (TRIP) has provided an update on its

" Psyched Wellness (CSE:PSYC) launches eCommerce fulfillment with ShipHero8

Psyched Wellness (PSYC) has officially launched with fulfillment partner ShipHero.

" Psyence (CSE:PSYG) exports pharma-grade psilocybin extract to the U.K.

Psyence (PSYG) has exported purified pharmaceutical-grade psilocybin mushroom extract to its contract development & manufacturing organization partner in the U.K.
  • Jon Brown
  • 2 mins
  • 20 January 2023 11:45 (EST)
  • 171

" Nova Mentis (CSE:NOVA) appoints Derek Ivany as Executive Chairman

Nova Mentis Life Science (NOVA) has announced the appointment of Derek Ivany to the position of Executive Chairman.

" Clearmind (CSE:CMND) adds results for a pre-clinical study for cocaine addiction treatment

Clearmind Medicine (CMND) found additional pre-clinical results in its research studies of MEAI and its effect on substance use disorder.

" Optimi Health (CSE:OPTI) expands functional mushroom sales network

Optimi Health (OPTI) is expanding its sales network in Canada.
  • Jon Brown
  • 2 mins
  • 17 January 2023 11:45 (EST)
  • 106

" Field Trip Health & Wellness (TSXV:FTHW) launches online therapy

Field Trip Health & Wellness (FTHW) launched Field Trip Online Therapy, a unique approach to psychotherapy.
Small Pharma team

" First Patient dosed in Small Pharma’s (TSXV:DMT) Phase I study

Small Pharma (DMT) announced that the first patient has been dosed in its Phase I study exploring intermuscular administration of SPL026.
Clearmind Medicine - CEO, Adi Zuloff Shani

" Clearmind Medicine (CSE:CMND) demonstrates efficacy of psychedelic-derived obesity treatment in pre-clinical trial

Clearmind Medicine (CMND) has announced positive pre-clinical results demonstrating the efficacy of its drug candidate MEAI.

" Algernon Pharmaceuticals (CSE:AGN) announces private subsidiary and SEC filing

Algernon (AGN) has formed a private subsidiary to advance its psychedelic DMT stroke program.